Search research articles
Contact Us
Filters
Showing results (61-70 of 85) with videos related to
Page
of 9
Sort By:
British Journal of Cancer
|
June 25, 2019
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
Daniel Morgensztern, Michal Rose, Saiama N Waqar, et al.
Oncotarget
|
November 17, 2016
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
Praveena S Thiagarajan, Xiaoliang Wu, Wei Zhang, et al.
Cancer Research
|
March 1, 2005
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
Patrick C Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, et al.
Cancer Research
|
May 11, 2011
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
Weiwen Fan, Zhe Tang, Lihong Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2019
Detection of NRG1 Gene Fusions in Solid Tumors
Sushma Jonna, Rebecca A Feldman, Jeffrey Swensen, et al.
JCO Precision Oncology
|
June 8, 2026
Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors
Chul Kim, Tolulope Adeyelu, Rohan Maniar, et al.
JTO Clinical and Research Reports
|
September 9, 2022
Characterization of <i>MET</i> Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
So Yeon Kim, Jun Yin, Stephen Bohlman, et al.
Cancer Research
|
January 7, 2006
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
Ramasamy Jagadeeswaran, Patrick C Ma, Tanguy Y Seiwert, et al.
Theranostics
|
June 7, 2021
Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC
Yayi He, Linsong Chen, Lishu Zhao, et al.
Cancer Cell
|
November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
David Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Page
of 9
Search research articles
Search
Showing results (61-70 of 85) with videos related to
Sort By:
Page
of 9
British Journal of Cancer
|
June 25, 2019
RRx-001 followed by platinum plus etoposide in patients with previously treated small-cell lung cancer
Daniel Morgensztern, Michal Rose, Saiama N Waqar, et al.
Oncotarget
|
November 17, 2016
Transcriptomic-metabolomic reprogramming in EGFR-mutant NSCLC early adaptive drug escape linking TGFβ2-bioenergetics-mitochondrial priming
Praveena S Thiagarajan, Xiaoliang Wu, Wei Zhang, et al.
Cancer Research
|
March 1, 2005
Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
Patrick C Ma, Ramasamy Jagadeeswaran, Simha Jagadeesh, et al.
Cancer Research
|
May 11, 2011
MET-independent lung cancer cells evading EGFR kinase inhibitors are therapeutically susceptible to BH3 mimetic agents
Weiwen Fan, Zhe Tang, Lihong Yin, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
April 17, 2019
Detection of NRG1 Gene Fusions in Solid Tumors
Sushma Jonna, Rebecca A Feldman, Jeffrey Swensen, et al.
JCO Precision Oncology
|
June 8, 2026
Integrated Molecular and Clinical Analysis of Thymic Epithelial Tumors
Chul Kim, Tolulope Adeyelu, Rohan Maniar, et al.
JTO Clinical and Research Reports
|
September 9, 2022
Characterization of <i>MET</i> Exon 14 Skipping Alterations (in NSCLC) and Identification of Potential Therapeutic Targets Using Whole Transcriptome Sequencing
So Yeon Kim, Jun Yin, Stephen Bohlman, et al.
Cancer Research
|
January 7, 2006
Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma
Ramasamy Jagadeeswaran, Patrick C Ma, Tanguy Y Seiwert, et al.
Theranostics
|
June 7, 2021
Genomic and transcriptional alterations in first-line chemotherapy exert a potentially unfavorable influence on subsequent immunotherapy in NSCLC
Yayi He, Linsong Chen, Lishu Zhao, et al.
Cancer Cell
|
November 22, 2024
Mutation burden and anti-PD-1 outcomes are not universally associated with immune cell infiltration or lymphoid activation
David Hsiehchen, Andrew Elliott, Joanne Xiu, et al.
Page
of 9